Business
Vicore Pharma Completes Enrollment in the Phase 2b ASPIRE Trial of Buloxibutid in Idiopathic Pulmonary Fibrosis
The randomized Phase 2b ASPIRE trial successfully completed planned enrollment of over 360 patients, reflecting strong execution and robust site engagement ASPIRE is designed to assess the effect of buloxibutid on forced vital capacity (FVC) over ...
About this update from Vicore Pharma Holding Ab
The randomized Phase 2b ASPIRE trial successfully completed planned enrollment of over 360 patients, reflecting strong execution and robust site engagement ASPIRE is designed to assess the effect of buloxibutid on forced vital capacity (FVC) over ...